Cell-Free Human Papillomavirus-DNA for Monitoring Treatment Response of Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Flaminia CampoJacopo ZocchiSilvia MorettoFrancesco MazzolaGerardo PetruzziMaria G DonàMaria BenevoloOreste IoccaArmando De VirgilioBarbara PichiValentina MancioccoRaul PelliniPublished in: The Laryngoscope (2021)
Currently, the follow-up protocol for HNSCC patients includes routine clinical evaluation and radiological imaging. Biomarkers to monitor this disease are not established. Considering its high specificity, cfHPV-DNA represents a potential confirmatory test in the case of positive positron emission tomography and computed tomography. In the near future, cfHPV-DNA could be used as a biomarker for monitoring the treatment response during the clinical trials of de-escalation therapy or immunotherapy. Larger sample sizes and the homologation of study protocols and methodology are needed to better establish its utility in the clinical practice. Laryngoscope, 2021.
Keyphrases
- cell free
- positron emission tomography
- computed tomography
- circulating tumor
- clinical practice
- clinical evaluation
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- single molecule
- chronic kidney disease
- pet imaging
- randomized controlled trial
- pet ct
- magnetic resonance imaging
- peritoneal dialysis
- circulating tumor cells
- mesenchymal stem cells
- stem cells
- bone marrow
- image quality
- mass spectrometry
- cell therapy
- double blind
- dual energy
- structural basis
- human health